SL SLS SELLAS Life Sciences Group, Inc. Common Stock Loading... : Investor Sentiment and Bull/Bear Views

The author argues SLS is a binary bet on REGAL, the first randomized Phase 3 test of GPS maintenance therapy in second-remission AML, with overall survival as the endpoint. The setup is supported by credible MSK/MD Anderson researchers, financing that kept the trial funded with about $138M in cash, and a batch-manufactured peptide format that avoids Dendreon-style bespoke production risk. The immediate catalyst is REGAL top-line data due this quarter; the main risks are a trial miss given weak prior non-randomized data, another warrant-heavy dilutive raise, and approval without commercial payoff.

The author is bullish on SELLAS Life Sciences because the CEO's recent LinkedIn posts are precise and confident and BlackRock disclosed an increased shareholding. The key catalyst is the ASH late-breaking abstract deadline coinciding with the announcement of the 80th REGAL event, which the author speculates means positive Phase 3 survival data was submitted. Positive data could make GPS a major AML asset and put SLS in play for a pharma buyout. Main risk is that the submission speculation is wrong and REGAL data disappoints.

The author is bullish on SLS because the CEO's recent LinkedIn posts are confident, BlackRock disclosed an increased stake, and the 80th REGAL event was announced on the same day as ASH's late-breaking abstract deadline. He reasons that if REGAL had failed, the company would not submit results to ASH, and positive Phase 3 survival data could make GPS a major AML asset and put SLS in play for a pharma buyout. The main risk is that the trial is a coin toss and the data could disappoint.